{"id":"verapamil-plus-lithium","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Polyuria/polydipsia"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Lithium toxicity (at elevated levels)"},{"rate":null,"effect":"Bradycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Verapamil blocks L-type calcium channels in cardiac and vascular tissue, slowing conduction and reducing contractility. Lithium inhibits inositol monophosphatase and glycogen synthase kinase-3, affecting intracellular signaling and neuroprotection. The combination may provide enhanced therapeutic effects in conditions requiring both cardiac rate control and neuropsychiatric stabilization, though the exact synergistic mechanism in this Phase 3 context requires clarification of the specific indication.","oneSentence":"Verapamil (a calcium channel blocker) combined with lithium (a mood stabilizer) works synergistically to modulate cardiac conduction and neuronal signaling pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:40:32.237Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bipolar disorder with cardiac arrhythmia or rate control requirement (investigational)"}]},"trialDetails":[{"nctId":"NCT05743751","phase":"NA","title":"Normothermic Machine Perfusion (NMP) Versus Hypothermic Machine Perfusion (HMP) in Human Kidney Transplantation","status":"UNKNOWN","sponsor":"Zhang Tianyu","startDate":"2023-03-03","conditions":"Kidney Transplantation","enrollment":60},{"nctId":"NCT00518947","phase":"PHASE3","title":"Pharmacotherapy of Treatment-Resistant Mania","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"1994-11","conditions":"Mania","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"verapamil plus lithium","genericName":"verapamil plus lithium","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Verapamil (a calcium channel blocker) combined with lithium (a mood stabilizer) works synergistically to modulate cardiac conduction and neuronal signaling pathways. Used for Bipolar disorder with cardiac arrhythmia or rate control requirement (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}